000125941 001__ 125941
000125941 005__ 20240228143342.0
000125941 0247_ $$2doi$$a10.1016/j.ijrobp.2016.02.025
000125941 0247_ $$2pmid$$apmid:27084659
000125941 0247_ $$2ISSN$$a0360-3016
000125941 0247_ $$2ISSN$$a1879-355X
000125941 0247_ $$2altmetric$$aaltmetric:5528624
000125941 037__ $$aDKFZ-2017-02065
000125941 041__ $$aeng
000125941 082__ $$a610
000125941 1001_ $$aHabl, Gregor$$b0
000125941 245__ $$aAcute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.
000125941 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2016
000125941 3367_ $$2DRIVER$$aarticle
000125941 3367_ $$2DataCite$$aOutput Types/Journal article
000125941 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524741777_17044
000125941 3367_ $$2BibTeX$$aARTICLE
000125941 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000125941 3367_ $$00$$2EndNote$$aJournal Article
000125941 520__ $$aThe purpose of this study was to compare safety and feasibility of proton therapy with that of carbon ion therapy in hypofractionated raster-scanned irradiation of the prostate, in a prospective randomized phase 2 trial.In this trial, 92 patients with localized prostate cancer were enrolled. Patients were randomized to receive either proton therapy (arm A) or carbon ion therapy (arm B) and treated with a total dose of 66 Gy(relative biological effectiveness [RBE]) administered in 20 fractions (single dose of 3.3 Gy[RBE]). Patients were stratified by the use of antihormone therapy. Primary endpoint was the combined assessment of safety and feasibility. Secondary endpoints were specific toxicities, prostate-specific antigen progression-free survival (PFS), overall survival (OS), and quality of life (QoL).Ninety-one patients completed therapy and have had a median follow-up of 22.3 months. Among acute genitourinary toxicities, grade 1 cystitis rates were 34.1% (39.1% in A; 28.9% in B) and 17.6% grade 2 (21.7% in A; 13.3% in B). Seven patients (8%) required urinary catheterization during treatment due to urinary retention, 5 of whom were in arm A. Regarding acute gastrointestinal toxicities, 2 patients treated with protons developed grade 3 rectal fistulas. Grade 1 radiation proctitis occurred in 12.1% (13.0% in A; 11.1% in B) and grade 2 in 5.5% (8.7% in A; 2.2% in B). No statistically significant differences in toxicity profiles between arms were found. Reduced QoL was evident mainly in fatigue, pain, and urinary symptoms during therapy and 6 weeks thereafter. All European Organization for Research and Treatment of Cancer QLQ-C30 and -PR25 scores improved during follow-up.Hypofractionated irradiation using either carbon ions or protons results in comparable acute toxicities and QoL parameters. We found that hypofractionated particle irradiation is feasible and may be safe. Due to the occurrence of gel in the rectal wall and the consecutive occurrence of 2 rectal fistulas, we stopped using the insertion of spacer gel. Longer follow-up is necessary for evaluation of PFS and OS. (Ion Prostate Irradiation (IPI); NCT01641185; ClinicalTrials.gov.).
000125941 536__ $$0G:(DE-HGF)POF3-315$$a315 - Imaging and radiooncology (POF3-315)$$cPOF3-315$$fPOF III$$x0
000125941 588__ $$aDataset connected to CrossRef, PubMed,
000125941 650_7 $$2NLM Chemicals$$aAndrogen Antagonists
000125941 650_7 $$0EC 3.4.21.77$$2NLM Chemicals$$aProstate-Specific Antigen
000125941 7001_ $$aUhl, Matthias$$b1
000125941 7001_ $$aKatayama, Sonja$$b2
000125941 7001_ $$aKessel, Kerstin A$$b3
000125941 7001_ $$aHatiboglu, Gencay$$b4
000125941 7001_ $$aHadaschik, Boris$$b5
000125941 7001_ $$0P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aEdler, Lutz$$b6$$udkfz
000125941 7001_ $$0P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aTichy, Diana$$b7$$udkfz
000125941 7001_ $$aEllerbrock, Malte$$b8
000125941 7001_ $$aHaberer, Thomas$$b9
000125941 7001_ $$0P:(DE-HGF)0$$aWolf, Maja B$$b10
000125941 7001_ $$0P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aSchlemmer, Heinz-Peter$$b11$$udkfz
000125941 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b12$$udkfz
000125941 7001_ $$aHerfarth, Klaus$$b13
000125941 773__ $$0PERI:(DE-600)1500486-7$$a10.1016/j.ijrobp.2016.02.025$$gVol. 95, no. 1, p. 435 - 443$$n1$$p435 - 443$$tInternational journal of radiation oncology, biology, physics$$v95$$x0360-3016$$y2016
000125941 909CO $$ooai:inrepo02.dkfz.de:125941$$pVDB
000125941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000125941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2ef631585610340ff425c9c31fcabd03$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000125941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000125941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)3d04c8fee58c9ab71f62ff80d06b6fec$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000125941 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000125941 9131_ $$0G:(DE-HGF)POF3-315$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vImaging and radiooncology$$x0
000125941 9141_ $$y2016
000125941 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000125941 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J RADIAT ONCOL : 2015
000125941 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000125941 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000125941 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000125941 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000125941 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000125941 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000125941 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000125941 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000125941 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000125941 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000125941 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000125941 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000125941 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000125941 9201_ $$0I:(DE-He78)E010-20160331$$kE010$$lRadiologie$$x1
000125941 980__ $$ajournal
000125941 980__ $$aVDB
000125941 980__ $$aI:(DE-He78)C060-20160331
000125941 980__ $$aI:(DE-He78)E010-20160331
000125941 980__ $$aUNRESTRICTED